EDIT
EDIT clinical trials: Editas Medicine, Inc.
Every trial on ClinicalTrials.gov where Editas Medicine, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 6
- Trials linked
- 6
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
EDIT on the catalyst calendar · EDIT registry changes
- Primary completion Jun 2029Sponsor estimatePhase 1/Phase 2NCT07894887EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)Editas Medicine, Inc. · Heterozygous Familial Hypercholesterolemia (HeFH)Not yet recruitingEDITLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2040Sponsor estimateNo phase registeredNCT06363760A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301Editas Medicine, Inc. · Sickle Cell DiseaseEnrolling by invitationEDITLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2025Sponsor estimatePhase 1/Phase 2NCT05444894EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)Editas Medicine, Inc. · Transfusion Dependent Beta ThalassemiaActive, not recruitingEDITLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2025Sponsor estimatePhase 1/Phase 2NCT04853576A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)Editas Medicine, Inc. · Sickle Cell DiseaseActive, not recruitingEDITLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 23, 2025Sponsor estimatePhase 1/Phase 2NCT03872479Single Ascending Dose Study in Participants With LCA10Editas Medicine, Inc. · Leber Congenital Amaurosis 10Unknown statusEDITLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 6, 2022ActualNo phase registeredNCT03396042Natural History Study of CEP290-Related Retinal DegenerationEditas Medicine, Inc. · BlindnessCompletedEDITLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 6 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner